Age-specific seroprevalence of serogroup C meningococcal serum bactericidal antibody activity and serogroup A, C, W135 and Y-specific IgG concentrations in the Turkish population during 2005

dc.contributor.authorCeyhan, Mehmet
dc.contributor.authorYildirim, Inci
dc.contributor.authorBalmer, Paul
dc.contributor.authorRiley, Christine
dc.contributor.authorLaher, Gouri
dc.contributor.authorAndrews, Nick
dc.contributor.authorSchultze, Viola
dc.date.accessioned2026-08-12T17:29:44Z
dc.date.issued2007
dc.departmentFırat Üniversitesi
dc.description.abstractLike many other developing countries; there is no accurate information about the antibody levels against Neisseria meningitidis in Turkey. We collected serum samples from four health centers located in different geographic regions and stratified according to age in order to obtain a baseline seroprevalence of protective antibodies to meningococcal serogroup C and provide data on seroprevalence of IgG antibodies to serogroups A, C, W135 and Y. Sera were tested for serum bactericidal antibodies (SBA) to serogroup C meningococci using rabbit serum as the complement source and by a bead based assay for serogroup A, C, W135 and Y-specific IgG. It was observed that 30% and 12% of individuals within the study population had SBA titers of >= 8 and >= 128, respectively. Overall; at least 70% of the population are susceptible (SBA titer < 8) to meningococcal serogroup C disease. The rate of susceptibility was highest in infants aged 7-12 months and young children (1-4 years). Regardless of age, for serogroup A, C, W135 and Y, 60.5%, 27.2%, 12.3% and 19.2% of subjects, respectively, had serogroup-specific IgG concentrations >= 2 mu g/mL. These data highlight that a large proportion of the Turkish population are susceptible to serogroups C, W135 and Y and should be considered, along with serogroup-specific disease incidence data, in future decisions on possible meningococcal vaccination programmes. (c) 2007 Elsevier Ltd. All rights reserved.
dc.identifier.doi10.1016/j.vaccine.2007.07.019
dc.identifier.endpage7237
dc.identifier.issn0264-410X
dc.identifier.issue41
dc.identifier.orcid0000-0002-7277-3550
dc.identifier.pmid17707957
dc.identifier.scopus2-s2.0-34848918872
dc.identifier.scopusqualityQ1
dc.identifier.startpage7233
dc.identifier.urihttps://doi.org/10.1016/j.vaccine.2007.07.019
dc.identifier.urihttps://hdl.handle.net/11508/55826
dc.identifier.volume25
dc.identifier.wosWOS:000250454900027
dc.identifier.wosqualityQ2
dc.indekslendigikaynakWeb of Science
dc.indekslendigikaynakScopus
dc.indekslendigikaynakPubMed
dc.language.isoen
dc.publisherElsevier Sci Ltd
dc.relation.ispartofVaccine
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanı
dc.rightsinfo:eu-repo/semantics/closedAccess
dc.snmzKA_WoS_20260511
dc.subjectmeningococcal
dc.subjectserum bactericidal antibody
dc.subjectseroprevalence
dc.titleAge-specific seroprevalence of serogroup C meningococcal serum bactericidal antibody activity and serogroup A, C, W135 and Y-specific IgG concentrations in the Turkish population during 2005
dc.typeArticle

Dosyalar